Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Karin Klenovsek"'
Autor:
Karin Klenovsek, Andrea Schneider, Uwe K. Appelt, Michael Mach, Birgit Bradel-Tretheway, Martin Messerle, Florian Weisel, Stipan Jonjić, Thomas Winkler
Publikováno v:
Blood
Volume 110
Issue 9
Volume 110
Issue 9
Severe disease associated with cytomegalovirus (CMV) infection is still a major problem in patients who undergo transplantation. Support of the patients' immune defense against the virus is a major goal in transplantation medicine. We have used the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7cf0d7f099243b9988377d741cf6cfb
https://doi.org/10.1182/blood-2007-06-095414
https://doi.org/10.1182/blood-2007-06-095414
Autor:
Peter Rohwer, Karin Klenovsek, Andrea Schneider, Michael Mach, Thomas Winkler, Uwe Ritter, Barbara J. Hebeis
Publikováno v:
The Journal of Experimental Medicine
Humoral immunity is maintained by long-lived plasma cells, constitutively secreting antibodies, and nonsecreting resting memory B cells that are rapidly reactivated upon antigen encounter. The activation requirements for resting memory B cells, parti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf890e3d289b37dc9bd879aaaca6b561
https://doi.org/10.1084/jem.20030091
https://doi.org/10.1084/jem.20030091
Publikováno v:
Blood. 108:619-619
Infections with cytomegalovirus are still a major clinical problem in immunosuppressed patients e.g. after bone marrow or stem cell transplantation. To prevent clinical overt disease resulting from disseminated virus infection, immunoprophylaxis and/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2870166648503870fdeb4bd0663b7bd
https://doi.org/10.1182/blood.v108.11.619.619
https://doi.org/10.1182/blood.v108.11.619.619
Publikováno v:
Nucleic Acids Research; Dec2002, Vol. 30 Issue 24, p5509-5516, 8p
Autor:
Leon V. Berhardt
Advances in Medicine and Biology. Volume 140 opens by discussing vascular endothelial growth factor, an attractive target for antiangiogenic therapy for glioblastoma. Although bevacizumab, a humanized anti-vascular endothelial growth factor antibody,
